MMP2 and renal fibrosis: In this study, we show that the pan-DUB inhibitor PR-619 reduces expression of mesenchymal markers, deposition of ECM proteins, expression of MMP2 and MMP9, the degree of apoptosis, macrophage infiltration, and the TGF-β1 mRNA level, and attenuates renal fibrosis.